What is probably more of an issue is that wide-scale bag holding will trigger new regulations that will make it much hard for startups to raise money in the future. Even if people want to invest it might prove impossible to raise money in practice.
The biotech IPO window was almost closed from ~2000 to 2012-2013. Look at it now! Companies with nothing more than a promise raising $150M+ at IPO. I haven't kept track, but it wouldn't surprise me if close to 100 biotechs have IPOed in the last 2-3 years.
At least 121 from Jan 2013, to Feb 2015:
http://www.forbes.com/sites/brucebooth/2015/03/20/biotech-ip...
And the Nasdaq biotech index (NBI) has skyrocketed, from 1,000 four years ago, to a recent peak of 4,000 before the plunge (after having barely moved for a decade previously).
Apparently most people's memories don't even go back as far as 2008.